Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P Hughes, Susan Branford, Deborah L White, John Reynolds, Rachel Koelmeyer, John F Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz Show all
Blood | AMER SOC HEMATOLOGY | Published : 2008
This work was supported in part by grants from Novartis Pharmaceuticals Australia and Amgen Australia. T. P. H. is a National Health and Medical Research Council Practitioner Fellow.